SPRO Stock Forecast: Spero Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.74
−10.17% on the day

The median 12-month analyst price target for Spero Therapeutics, Inc. is $6. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 32 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$43.2M
Ticker Nerd rank
32/ 100
Median analyst target
$6.00
Analysts covering
3
Revenue$0.0−100.0% y/y
Operating income−$9.9M
Net income−$9.6M
Free cash flow−$5.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−25.8%
1M
−39.2%
YTD
−68.2%
1Y
−67.2%
From 52W high
−75.1%
From 52W low
0.0%
$0.74
$2.98
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Spero Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
32/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
99
Value
85
Volatility
36
Revisions
35
Quality
29
Momentum
15
Issuance
13
Accruals
8

Growth (99): Sales and profits are climbing, and climbing faster than before.

Accruals (8): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

SPRO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SPRO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00$5.00$6.00Jan 26Apr 26Jul 26Oct 26SPROHigh $6.00Median $6.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
2
Buy
1
Hold
0
Sell
$4.00
Low
$6.00
Median
$6.00
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
28 Oct 2026Cantor FitzgeraldInitiatesOverweight$6.00
14 Sept 2026HC Wainwright & Co.MaintainsBuy$5.00 → $6.00
30 Jan 2025HC Wainwright & Co.ReiteratesBuy$5.00
20 Dec 2024Evercore ISI GroupDowngradeIn-Line—
2 Dec 2024HC Wainwright & Co.ReiteratesBuy—
18 Nov 2024TD CowenDowngradeHold—
15 Nov 2024Cantor FitzgeraldReiteratesOverweight—
4 Nov 2024HC Wainwright & Co.MaintainsBuy—
3 Oct 2024HC Wainwright & Co.ReiteratesBuy—
6 Aug 2024Cantor FitzgeraldReiteratesOverweight—
6 Aug 2024HC Wainwright & Co.ReiteratesBuy—
6 Aug 2024TD CowenUpgradeBuy—
16 May 2024HC Wainwright & Co.ReiteratesBuy—
4 Apr 2024Cantor FitzgeraldReiteratesOverweight—
18 Mar 2024HC Wainwright & Co.ReiteratesBuy—
14 Nov 2023HC Wainwright & Co.ReiteratesBuy—
5 Sept 2023HC Wainwright & Co.ReiteratesBuy—
14 Aug 2023HC Wainwright & Co.MaintainsBuy—
1 Aug 2023HC Wainwright & Co.ReiteratesBuy—
20 July 2023HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for SPRO.

Market Radar

This page is one stock. Monday covers all of them.

SPRO appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

SPRO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Spero Therapeutics, Inc. returned −67.2% against +6.9% for the S&P 500, dividends included.

SPRO vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120140Jan 26Apr 26Jul 26Oct 26SPROS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SPRO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
1.0×

Cheaper than 65% of US stocks

Price / book
57.1×

Cheaper than 1% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
16.9%

Higher than 75% of US stocks

Net margin
—
Returns & dividend
Return on equity
−216.4%

Higher than 7% of US stocks

Return on assets
5.3%

Higher than 77% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Spero Therapeutics, Inc. has a market value of $43.2M.

  • Revenue in the twelve months to 30 June 2026: $43.0M. The latest quarter shrank 100.0% year on year.

  • Net income over the same four quarters: $7.4M, a 17.2% net margin.

  • Diluted earnings per share, trailing twelve months: $0.11.

  • Free cash flow in the twelve months to 30 June 2026: $19.6M.

  • Shares outstanding: 58.1M.

  • Spero Therapeutics, Inc. employs 25 people — $1.7M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

SPRO and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SPROSpero Therapeutics, Inc.$43.2M32
ELOXEloxx Pharmaceuticals, Inc.$43.1M18
CRBPCorbus Pharmaceuticals Holdings, Inc.$42.4M12
ANVSAnnovis Bio, Inc.$44.1M16
OSTXOS Therapies, Inc.$42.0M23
GANXGain Therapeutics, Inc.$44.5M32
BMEABiomea Fusion, Inc.$41.7M46

Take a look at SPRO’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Spero Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about SPRO

What is the SPRO stock price forecast for 2026-2027?

The median 12-month analyst price target for Spero Therapeutics, Inc. is $6, with estimates ranging from $4 to $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SPRO stock a buy right now?

Of the 3 analysts covering Spero Therapeutics, Inc., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Spero Therapeutics, Inc. 32 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SPRO?

As at 21 Nov 2026, Spero Therapeutics, Inc. ranks 32 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (99 of 100).

Will SPRO stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts is $6, and Ticker Nerd's factor model ranks Spero Therapeutics, Inc. 32 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SPRO stock forecast for 2030?

No analyst covering Spero Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SPRO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $6 over the next 12 months.

How has SPRO stock performed over the past year?

Spero Therapeutics, Inc. returned -67.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Spero Therapeutics, Inc. do?

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for multi-drug resistant bacterial infections and rare diseases. Spero Therapeutics advances a pipeline of product candidates aimed at serious infectious and immune-mediated conditions, including tebipenem pivoxil, an oral carbapenem antibiotic for complicated urinary tract infections, SPR720 for nontuberculous mycobacterial pulmonary disease, SPR206 for difficult Gram-negative infections, and SP001 for immune-mediated disease.

Company

About Spero Therapeutics, Inc.

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for multi-drug resistant bacterial infections and rare diseases. Spero Therapeutics advances a pipeline of product candidates aimed at serious infectious and immune-mediated conditions, including tebipenem pivoxil, an oral carbapenem antibiotic for complicated urinary tract infections, SPR720 for nontuberculous mycobacterial pulmonary disease, SPR206 for difficult Gram-negative infections, and SP001 for immune-mediated disease. The company’s work centers on addressing high unmet medical needs in hospital, outpatient, and specialty care settings through novel small-molecule and biologic therapies. Headquartered in Cambridge, Massachusetts, Spero Therapeutics plays a role in the biopharmaceutical market by focusing on differentiated medicines for patients with limited treatment options.

CEO Ms. Esther P. Rajavelu · 25 employees · United States · https://sperotherapeutics.com